Letrozole (Femara®) is a more effective anti-proliferative agent than tamoxifen irrespective of ErbB1 and/or ErbB2 positive status: Evidence from a phase III randomized trial of neoadjuvant endocrine therapy for postmenopausal women with estrogen receptor positive primary breast cancer

Breast Cancer Research and Treatment

Volumn 69, Issue 3, 2001, Pages 211-

  Ellis, M J ^a   Jaenicke, F ^a   Llombart Cussac, A ^a   Mauriac, L ^a   Miller, W R ^a   Evans, D B ^a   Brady, C ^a   Dugan, M ^a   Quebe Fehling, E ^a   Borgs, M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0005921855     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)